Synlett 2005(15): 2376-2378  
DOI: 10.1055/s-2005-872667
LETTER
© Georg Thieme Verlag Stuttgart · New York

Ring Enlargement of Enantiopure 1,2-Oxazines to 1,2-Oxazepine Derivatives and Their Palladium-Catalyzed Couplings

Ahmed Al-Harrasi, Hans-Ulrich Reissig*
Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, 14195 Berlin, Germany
Fax: +49(30)83855367; e-Mail: hans.reissig@chemie.fu-berlin.de;
Further Information

Publication History

Received 5 July 2005
Publication Date:
07 September 2005 (online)

Abstract

Phase-transfer-catalyzed cyclopropanation of enantio­pure 1,2-oxazine derivatives anti-1a,b or syn-1 followed by solvo­lysis of the resulting geminal dibromocyclopropane intermediates afforded the expected ring-expanded products, namely 1,2-oxazepines anti-3a,b or syn-3. These heterocycles could be further substituted by use of their bromoalkenyl group employing ­palladium-catalyzed coupling reactions, which smoothly led to new enantiopure 1,2-oxazepine derivatives anti-4-anti-8.

4

Typical Procedure, conversion of anti -1a into anti -3a.
A solution of NaOH (0.60 g) and KF (4.10 g) in H2O (4.10 mL) was added to a vigorously stirred solution of anti-1a (0.50 g, 1.64 mmol) in CHBr3 (2.70 mL) containing benzyltriethylammonium chloride (5.5 mg). The biphasic mixture was stirred for 2 d at r.t. and then diluted with H2O (8 mL) and extracted with Et2O. The combined ethereal extracts were washed with brine, dried (Na2SO4) and concentrated. The excess CHBr3 was removed in vacuum. The residue was purified by column chromatography (silica gel, hexane-EtOAc, 4:1) to give 2a as colorless liquid (511 mg, 65%, dr 68:32).
Dibromocyclopropane derivative 2a was refluxed for 20 h in a solution of anhyd K2CO3 (0.87 g, 6.27 mmol) in MeOH (7 mL) under Ar atmosphere. The mixture was cooled to r.t., diluted with H2O and extracted with CH2Cl2. The combined organic extracts were dried (Na2SO4) and concentrated. The product was purified by column chromatography (silica gel, hexane-EtOAc, 9:1) to yield 241 mg (53%) of anti-3a as colorless oil.
Analytical data for (3R,4′S)-2-benzyl-5-bromo-3-(2′,2′-dimethyl-1′,3′-dioxolan-4′-yl)-4,4-dimethoxy-2,3,4,7-tetrahydro-1,2-oxazepine: [α]D 22 -84.2 (c 0.45, CHCl3). 1H NMR (500 MHz, CDCl3): δ = 1.33, 1.36 (2 s, 3 H each, Me), 3.19, 3.29 (2 s, 3 H each, OMe), 3.28 (d, J = 5.6 Hz, 1 H, 3-H), 4.07 (dd, J = 8.4, 8.8 Hz, 1 H, 5′-H), 4.11 (dd, J = 8.0, 8.4 Hz, 1 H, 5′-H), 4.29, 4.34 (2 d, J = 14.0 Hz, 1 H each, NCH2), 4.31 (mc, 1 H, 4′-H), 4.37 (dd, J = 1.1, 13.5 Hz, 1 H, 7-H), 4.47 (dd, J = 0.8, 13.5 Hz, 1 H, 7-H), 6.70 (dd, J = 0.8, 1.1 Hz, 1 H, 6-H), 7.24-7.39 (m, 5 H, Ph) ppm. 13C NMR (126 MHz, CDCl3): δ = 25.7, 26.3 (2 q, CH3), 49.0, 49.1 (2 q, OMe), 58.1 (t, NCH2), 63.6 (t, C-7), 66.7 (d, C-3), 67.2 (t, C-5′), 74.9 (d, C-4′), 99.2 (d, C-2′), 108.5 (d, C-6), 108.9 (s, C-4), 127.1, 128.2, 128.6, 138.0 (3 d, s, Ph), 135.3 (s, C-5) ppm. IR (KBr): ν = 3090-3030 (=C-H), 2985-2845 (C-H), 1635 (C=C) cm-1. MS (EI, 80 eV, 100 °C): m/z (%) = 429 (1) [M]+, 427 (1) [M]+, 414 (1) [M - CH3]+, 412 (1) [M - CH3]+, 398 (0.4) [M - OCH3]+, 396 (0.4) [M - OCH3]+, 329 (6) [M - CH5H9O2]+, 327 (6) [M - CH5H9O2]+, 91 (100) [CH2Ph]+. Anal. Calcd for C19H20BrNO5 (428.3): C, 53.28; H, 6.12; N, 3.27. Found: C, 53.10; H, 5.91; N, 2.68. HRMS (EI, 80 eV, 100 °C): m/z calcd for C19H20 79BrNO5: 427.09943; found: 427.09947; m/z calcd for C19H20 81BrNO5: 429.09744; found: 429.09738.